Meridian Funds released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. U.S. equity markets experienced a quarter shaped by optimism and caution. Market sentiment cooled due to mixed signals from the Fed. Large caps rose 17.4% for the year, small caps gained 12.8%. Value stocks outperformed growth, returning 3.3% versus 1.2% for the quarter.

Tandem Diabetes Care, Inc. was highlighted as one of the leading contributors in the Meridian Growth Fund’s fourth-quarter 2025 investor letter. Tandem Diabetes Care, Inc. offers technology solutions for people living with diabetes. The company’s shares traded between $9.98 and $37.93 over the past 52 weeks and closed at $20.20 per share on January 26, 2026.

The Meridian Growth Fund’s fourth quarter 2025 investor letter mentioned Tandem Diabetes Care, Inc.’s advanced insulin delivery technologies for patients with diabetes. The company’s automated insulin delivery systems are well-positioned in a sizable and expanding market. Tandem Diabetes Care, Inc. has a market capitalization of $1.37 billion.

Tandem Diabetes Care, Inc. is not among the 30 most popular stocks among hedge funds. While the company has potential as an investment, the Fund believes certain AI stocks offer greater upside potential. The Fund continues to focus on high-quality businesses with strong competitive advantages and sustainable earnings growth.

For more insights on Tandem Diabetes Care, Inc. and other stocks discussed by Jim Cramer, visit the related articles. Check out the hedge fund investor letters Q4 2025 page for more investor letters from leading investors. Explore “The Best and Worst Dow Stocks for the Next 12 Months” and “10 Unstoppable Stocks That Could Double Your Money” for further reading.

Read more at Yahoo Finance: Improved Growth Outlook and Better-Than-Expected Results Boosted Tandem Diabetes Care (TNDM) in Q4